On the influence of protein binding on pharmacological activity of drugs

Journal of Pharmaceutical Sciences

Volumn 99, Issue 4, 2010, Pages 2153-2165

  Berezhkovskiy, Leonid M ^a  

^a GENENTECH INC   (United States)

Author keywords

Bioavailability; Clearance; Dispersion model; Drug efficiency; Drug exposure; Drug receptor binding; Parallel tube model; Protein binding; Tissue plasma partitioning; Well stirred model

Indexed keywords

ARTICLE; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; PROTEIN BINDING;

EID: 77949821065     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21958     Document Type: Article

References (16)

1. Trainor GL. 2007. The importance of plasma protein binding in drug discovery. Expert Opin Drug Metab Toxicol 2:51-64.
2. Berezhkovskiy LM. 2008. Some features of the kinetics and equilibrium of drug binding to plasma proteins. Expert Opin Drug Metab Toxicol 4:1479-1498.
3. Berezhkovskiy LM. 2004. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci 93:364-374.
4. Christensen H, Baker M, Tucker GT, Rostami-Hodjegan A. 2006. Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci 95: 2778-2787.
5. Berezhkovskiy LM. 2009. Consideration of the linear concentration increase of the unbound drug fraction in plasma. J Pharm Sci 98:383-393.
6. Benet LZ, Hoener B. 2002. Changes in plasma protein binding have little clinical relevance. Clin Pharm Ther 71:115-121.
7. Roberts MS, Rowland M. 1986. A dispersion model of hepatic elimination: 2. Steady-state considerations - influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. Pharmacokinet Biopharm 14:261-288.
8. Roberts MS, Rowland M. 1986. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. Pharmacokinet Biopharm 14:227-260.
9. Roberts MS, Rowland M. 1986. Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: Analysis with a dispersion model. J Pharm Pharmacol 38:177-181.
10. Diaz-Garcia JM, Evans AM, Rowland M. 1992. Application of the axial dispersion model of hepatic drug elimination to the kinetics of diazepam in the isolated perfused rat liver. J Pharmacokinet Biopharm 20:171-193.
11. Berezhkovskiy LM. 2009. Prediction of the possibility of the secondary peaks of iv bolus drug plasma concentration time curve by the model that directly takes into account the transit time through the organ. J Pharm Sci, in Early View.
12. Berezhkovskiy LM. 2007. On the determination of the time delay in reaching the steady state drug concentration in the organ compared to plasma. J Pharm Sci 96:3432-3443.
13. Berezhkovskiy LM. 2009. Determination of mean residence time of drug in plasma and the influence of the initial drug elimination and distribution on the calculation of pharmacokinetic parameters. J Pharm Sci 98:748-762.
14. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
15. Korn GA, Korn TM. 1961. Mathematical handbook for scientists and engineers. New York: McGraw-Hill, Inc.
16. Copeland RA, Pompliano DL, Meek TD. 2006. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5: 730-739.